Were Paula Green’s Twist Bioscience (TWST) share sales open‑market transactions?

Yes. The Form 4 classifies Paula Green’s June 15, 2026 transactions as open‑market sales of Twist Bioscience common stock, coded as “S,” with weighted average sale prices disclosed and additional trade‑level detail available upon request from the company or regulators.

Twist Bioscience SVP sells shares after option exercise

Twist Bioscience Corp SVP of Human Resources Paula Green reported option exercises and share sales.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Twist Bioscience Corp SVP of Human Resources Paula Green reported option exercises and share sales. On June 15, 2026, she exercised employee stock options for 26,137 shares of common stock at an exercise price of $23.33 per share. The same day, she made open‑market sales of 24,109 shares at a weighted average price of $81.6233 and 2,028 shares at a weighted average price of $82.1655. After these transactions, she directly owned 120,705 shares of Twist Bioscience common stock.

Insider Trade Summary

Exercise and Sale: 26,137 shares ($1.52M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Green Paula

Role SVP of Human Resources

Sold 26,137 shs ($2.13M)

Approx. gross sale proceeds $2.13M

Approx. exercise cost $610K

Approx. pre-tax spread $1.52M

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	26,137	$0.00	$0.00
Exercise	Common Stock	26,137	$23.33	$610K
Sale	Common Stock	24,109	$81.6233	$1.97M
Sale	Common Stock	2,028	$82.1655	$167K

Holdings After Transaction: Employee Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 120,705 shares (Direct)

Footnotes (3)

F1. Represents the weighted average sales price per share. The shares sold at prices ranging from $81.06 to $81.995 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $82.10 to $82.18 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Open-market sale 1: 24,109 shares at $81.6233 Open-market sale 2: 2,028 shares at $82.1655 Options exercised: 26,137 shares at $23.33 +3 more

6 metrics

Open-market sale 1 24,109 shares at $81.6233 Common stock sale on June 15, 2026

Open-market sale 2 2,028 shares at $82.1655 Common stock sale on June 15, 2026

Options exercised 26,137 shares at $23.33 Employee stock option exercise on June 15, 2026

Shares owned after transactions 120,705 shares Direct common stock ownership after June 15, 2026 trades

Net shares sold 26,137 shares Net share reduction from combined exercise and sales

Option expiration October 23, 2029 Expiration date of exercised employee stock option grant

Key Terms

weighted average sales price, Employee Stock Option (right to buy), derivative security, vested

4 terms

weighted average sales price financial

"Represents the weighted average sales price per share."

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vested financial

"25% of the shares subject to the option vested on October 24, 2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report for Paula Green?

Twist Bioscience reported that SVP of Human Resources Paula Green exercised employee stock options for 26,137 shares and sold 26,137 common shares in open‑market transactions on June 15, 2026, while continuing to hold a substantial remaining stake in the company.

How many Twist Bioscience (TWST) shares did Paula Green sell and at what prices?

Paula Green sold 24,109 Twist Bioscience common shares at a weighted average price of $81.6233 and 2,028 shares at a weighted average price of $82.1655 on June 15, 2026, according to the Form 4 insider trading disclosure.

What stock options did Paula Green exercise at Twist Bioscience (TWST)?

Paula Green exercised employee stock options covering 26,137 Twist Bioscience common shares at an exercise price of $23.33 per share. These options were part of a grant that vested over time, including monthly vesting following an initial 25% vesting date.

How many Twist Bioscience (TWST) shares does Paula Green own after the Form 4 transactions?

After exercising options and selling 26,137 shares, Paula Green directly owns 120,705 Twist Bioscience common shares. This post‑transaction holding figure comes from the Form 4 and reflects her remaining direct equity stake following the June 15, 2026 trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Paula

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP of Human Resources

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		M		26,137	A	$23.33	146,842	D
Common Stock	06/15/2026		S⁽¹⁾		24,109	D	$81.6233	122,733	D
Common Stock	06/15/2026		S⁽²⁾		2,028	D	$82.1655	120,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$23.33	06/15/2026		M			26,137	⁽³⁾	10/23/2029	Common Stock	26,137	$0	0	D

Explanation of Responses:

1. Represents the weighted average sales price per share. The shares sold at prices ranging from $81.06 to $81.995 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $82.10 to $82.18 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Judy Yan, as Attorney-in-Fact for Paula Green	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR